

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 Jul 2026

Simultaneous effect of tacrolimus drops and PRP and its comparison with artificial tacrolimus drops in the treatment of chronic dry eye in patients referred to the hospital

Protocol summary

Study aim

Simultaneous effect of tacrolimus drops and PRP and its comparison with artificial tacrolimus drops in the treatment of chronic dry eye in patients referred to the hospital

Design

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 2 on 18 patients. In order to randomize, the block randomization method will be used.

Settings and conduct

In this study, all patients with renal impairment who referred to Shafa Hospital will be enrolled. Patients will be randomly divided into 3 groups based on 6 blocks. The sample size for each study group is 6. A total of 18 patients will be examined. Patients, doctor and data analyzer will be blind.

Participants/Inclusion and exclusion criteria

Inclusion criteria: patients over 18 years, Corneal staining, Schirmer test is less than 5 mm in 5 minutes, BUT test is less than 5 seconds. Exclusion criteria: pregnancy, lactation, history of glaucoma and previous surgery or trauma, use of eye drops except for artificial tears, use of contact lenses.

Intervention groups

Intervention group 1: Patients receive only artificial tear drops Intervention group 2: Patients receive only tacrolimus drops Intervention group 3: Patients receive a combination of tacrolimus drops with PRP

Main outcome variables

BUT test; Corneal staining; Schirmer test

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20211011052725N1**

Registration date: **2021-12-24, 1400/10/03**

Registration timing: **prospective**

Last update: **2021-12-24, 1400/10/03**

Update count: **0**

Registration date

2021-12-24, 1400/10/03

Registrant information

Name

farzane barzegarpur

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 34 3428 2227

Email address

barzegarf1368@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-01-10, 1400/10/20

Expected recruitment end date

2022-07-11, 1401/04/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Simultaneous effect of tacrolimus drops and PRP and its comparison with artificial tacrolimus drops in the treatment of chronic dry eye in patients referred to the

hospital

Public title

Effect of tacrolimus drops and PRP in the treatment of chronic dry eye

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Patients over 18 years Corneal staining Schirmer test is less than 5 mm in 5 minutes BUT test is less than 5 seconds.

Exclusion criteria:

Pregnancy Lactation Pregnancy, lactation, history of glaucoma and previous surgery and trauma Use of eye drops other than artificial tears, and use of contact lenses.

Age

From **18 years** old

Gender

Both

Phase

2

Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser

Sample size

Target sample size: **18**

Randomization (investigator's opinion)

Randomized

Randomization description

Patients will be randomly divided into three groups. Randomization tool will be random sequence generation software that in addition to simple randomization, these random sequence generation software are able to generate random sequence by blocking method. In order to randomize, the block randomization method will be used. Block randomization is to make sure that exactly the same number of participants enter the study groups. The advantage of block randomization is that the balance of the number of participants in each group is guaranteed. For this purpose, 6 blocks will be formed and in each block, 2 people from intervention group 1, 2 people from intervention group 2 and 2 people in intervention group 3 will be placed. A total of 3 blocks will be considered to reach the sample size. For concealment, random allocation concealment will be used, which is the method used to execute a random sequence on the study participants, so that the assigned group is not known before the individual is assigned. Using opaque envelopes sealed with a random sequence, in this method, each of the random sequences created is recorded on a card and the cards are placed inside the envelopes in order. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the letter envelopes are glued and placed in a box, respectively. the door At the beginning of the registration of participants, based on the order of entry of eligible participants into the study,

one of the envelopes of the letter is opened in order and the assigned group of the participant is revealed.

Blinding (investigator's opinion)

Double blinded

Blinding description

Patients will be unaware and blind to the type of drugs. In order to blind, the desired drops are provided to patients in similar packages and in coded form, and patients will not be aware of the content of their medication. Patients will be aware that they will be randomly assigned to one of three treatment groups, but will be unaware of which treatment will be provided in that group. The physician also knows that patients will be anesthetized in three different ways, but will not know which procedure will be performed for each patient. The data collection officer, analyst and outcome assessor will collect and analyze information based on groups 1, 2 and 3 and will not be aware of the type of treatment provided in the groups. They will be kept blind.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Kerman University of Medical Sciences

Street address

Shafa Educational and Medical Center, Kowsar Boulevard

City

Kerman

Province

Kerman

Postal code

7618751151

Approval date

2020-04-27, 1399/02/08

Ethics committee reference number

IR.KMU.REC.1399.075

Health conditions studied

1

Description of health condition studied

Dry eye syndrome

ICD-10 code

H04.12

ICD-10 code description

Dry eye syndrome

Primary outcomes

1

Description

BUT test (Fluorescein disappears from Fornix)

Timepoint

One week, one month and three months after starting treatment

Method of measurement

Clinical examination of the patient - per second

2

Description

Corneal staining

Timepoint

One week, one month and three months after starting treatment

Method of measurement

Clinical examination of the patient

3

Description

Schirmer test

Timepoint

One week, one month and three months after starting treatment

Method of measurement

Clinical examination of the patient - In millimeters per minute

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group 1: Patients receive only artificial tear drops. Patients will use one drop three times a day, each time at eight-hour intervals. 10 ml drops will be for a patient's dose of one month. This amount will be repeated for the second and third month.

Category

Treatment - Drugs

2

Description

Intervention group 2: Patients receive only tacrolimus drops. One mg of tacrolimus is dissolved in five mg of buffer phosphate and given to the patient in sterile eye drops. Patients will use one drop three times a day, each time at eight-hour intervals. 10 ml drops will be for a patient's dose of one month. This amount will be repeated for the second and third month.

Category

Treatment - Drugs

3

Description

Intervention group 3: Patients receive a combination of tacrolimus drops with PRP. One mg of tacrolimus is dissolved in 5 mg of buffer phosphate and after mixing with 5 ml of autologous PRP in sterile eye drops will be given to the patient. Patients will use one drop three times a day, each time at eight-hour intervals. 10 ml drops will be for a patient's dose of one month. This amount will be repeated for the second and third month.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shafa Educational and Medical Center

Full name of responsible person

Farzaneh Barzegarpur

Street address

Shafa Educational and Medical Center, Kowsar Boulevard

City

Kerman

Province

Kerman

Postal code

7618751151

Phone

+98 34 3211 5780

Email

shafahospital@kmu.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kerman University of Medical Sciences

Full name of responsible person

Akbar Gholi Zadeh

Street address

Shafa Educational and Medical Center, Kowsar Boulevard

City

Kerman

Province

Kerman

Postal code

7618751151

Phone

+98 34 3211 5780

Email

shafahospital@kmu.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor

organization/entity?

Yes

Title of funding source

Kerman University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Ophthalmology

Street address

No.25, Emam Reza blv, Rafsanjan

City

Kerman

Province

Kerman

Postal code

7618751151

Phone

+98 34 3428 2227

Email

barzegarf1368@yahoo.com

Person responsible for updating data**Person responsible for general inquiries****Contact****Name of organization / entity**

Kerman University of Medical Sciences

Full name of responsible person

Farzaneh Barzegarpur

Position

resident

Latest degree

Medical doctor

Other areas of specialty/work

Ophthalmology

Street address

No.25, Emam Reza blv, Rafsanjan

City

Kerman

Province

Kerman

Postal code

7618751151

Phone

+98 34 3428 2227

Email

barzegarf1368@yahoo.com

Contact**Name of organization / entity**

Kerman University of Medical Sciences

Full name of responsible person

Farzaneh Barzegarpur

Position

resident

Latest degree

Medical doctor

Other areas of specialty/work

Ophthalmology

Street address

No.25, Emam Reza blv, Rafsanjan

City

Kerman

Province

Kerman

Postal code

7618751151

Phone

+98 34 3428 2227

Email

barzegarf1368@yahoo.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Kerman University of Medical Sciences

Full name of responsible person

Farzaneh Barzegarpur

Position

resident

Latest degree

Medical doctor

Other areas of specialty/work